机译:更新分析LCAR-B38M的阶段1,嵌合抗原受体T细胞疗法的阶段1,对B细胞成熟抗原的嵌合抗原受体T细胞疗法,复发/难治性多发性骨髓瘤患者
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Natl Local Joint Engn Res Ctr Biodiagnost &
Bioth Affiliated Hosp 2 Xian;
Xi An Jiao Tong Univ Natl Local Joint Engn Res Ctr Biodiagnost &
Bioth Affiliated Hosp 2 Xian;
Xi An Jiao Tong Univ Dept Clin Lab Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Clin Lab Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Nanjing Legend Biotech Nanjing Jiangsu Peoples R China;
Nanjing Legend Biotech Nanjing Jiangsu Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
Xi An Jiao Tong Univ Dept Hematol Affiliated Hosp 2 Xian Shaanxi Peoples R China;
机译:更新分析LCAR-B38M的阶段1,嵌合抗原受体T细胞疗法的阶段1,对B细胞成熟抗原的嵌合抗原受体T细胞疗法,复发/难治性多发性骨髓瘤患者
机译:B细胞成熟抗原特异性嵌合抗原受体T细胞用于复发或难治多骨髓瘤:META分析
机译:首先在与GSK2857916进行的人类研究中,将与微管破坏剂缀合的抗体药物,其针对复发/难治多骨髓瘤(MM)的患者中针对B细胞成熟抗原(BCMA)的抗原(BCMA):研究BMA117159部分1剂量升级
机译:提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:LCAR-B38M(针对B细胞成熟抗原的嵌合抗原受体T细胞疗法)在复发或难治性多发性骨髓瘤患者中进行的1期开放标签研究
机译:PCN20与抗BCMA嵌合抗原受体(CAR)T细胞治疗的整体响应和完全应答,用于复发和难治性多骨髓瘤(RRMM):系统审查和荟萃分析